1. Pink Sheet

Repurposing Leptin (Part 2): It Really Is A One-In-A-Million Drug

 
• By Michael McCaughan

Two decades after the “obesity gene” was the hottest story in biotech, a product from that research is finally going to reach the market. But it is for a disease that occurs in about .0001% of the US population.

Leptin’s long path to the US market appears to be ending at last: following a positive recommendation by a Food & Drug Administration advisory committee, AstraZeneca PLC should be cleared to launch Myalept (metreleptin) early in 2014.

That comes nearly 20 years after the development of the compound began, and after ownership has been transferred among four...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More from Pathways & Standards